VIR
NASDAQVir Biotechnology Inc.
News · 26 weeks72+43%
2025-12-142026-06-07
Mix2790d
- Insider14(52%)
- SEC Filings5(19%)
- Other4(15%)
- Offering2(7%)
- Earnings1(4%)
- M&A1(4%)
Latest news
25 items- INSIDERDirector Napolitano Janet sold $30,240 worth of shares (3,200 units at $9.45) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 21,216 units (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- INSIDERSVP, Chief Accounting Officer Sabatini Brent sold $3,582 worth of Common Stock (379 units at $9.45) as part of a pre-agreed trading plan, decreasing direct ownership by 0.61% to 61,902 units (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- INSIDERDirector Sigal Charles Elliott was granted 8,000 shares, increasing direct ownership by 25% to 39,806 units (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- INSIDERDirector Napolitano Janet was granted 8,000 shares, increasing direct ownership by 49% to 24,416 units (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- INSIDERDirector More Robert J was granted 8,000 shares, increasing direct ownership by 20% to 48,656 units (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- INSIDERDirector Hatfield Jeffrey S. was granted 8,000 shares, increasing direct ownership by 25% to 39,806 units (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- INSIDERDirector Farid Ramy was granted 8,000 shares, increasing direct ownership by 33% to 32,000 units (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- INSIDERDirector Bischofberger Norbert W was granted 8,000 shares, increasing direct ownership by 60% to 21,333 units (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- SECVir Biotechnology Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders8-K - Vir Biotechnology, Inc. (0001706431) (Filer)
- PRVir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026- Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48 subgroup analysis from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for poster tour by EASL Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta at the upcoming EASL Congress 2026 in Barcelona, Spain, May 27-30, 2026. Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chro
- PR"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming TherapiesIssued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid tumors are suddenly among the busiest battlegrounds in oncology — and a new natural killer cell engager just joined the field SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary — Until very recently, the immuno-oncology revolution had largely passed several of the most lethal solid tumor categories by. Checkpoint inhibitors, which transformed outcomes in melanoma, lung cancer, and renal cell carcinoma, have struggled to deliver meaningful benefit for the m
- SECVir Biotechnology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Vir Biotechnology, Inc. (0001706431) (Filer)
- PRVir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results- Global strategic collaboration with Astellas to advance PSMA-targeted, PRO-XTEN® dual-masked T-cell engager (TCE) VIR-5500 closed and first patient dosed in Phase 1 dose-expansion cohorts in patients with late-line metastatic prostate cancer - Company will present complete Week 96 Phase 2 SOLSTICE data on its combination regimen for chronic hepatitis delta (CHD) at the European Association for the Study of the Liver (EASL) Congress - Strong financial position with $809.3 million in cash and investments as of March 31, 2026, excluding $315 million combined Astellas upfront payment1 and equity investment to be received in the second quarter of 2026 - Conference call scheduled for May
- PRVir Biotechnology to Participate in Bank of America Securities 2026 Healthcare ConferenceVir Biotechnology, Inc. (NASDAQ:VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Bank of America Securities 2026 Healthcare Conference on Tuesday, May 12 at 4:20 p.m. PT / 7:20 p.m. ET in Las Vegas, Nevada. A live webcast of the fireside chat will be available at https://investors.vir.bio and will be archived for 30 days. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs fo
- INSIDERDirector Sato Vicki L sold $221,025 worth of shares (22,000 units at $10.05) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,078,391 units (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- INSIDERPresident and CEO De Backer Marianne disposed of 233,532 shares and acquired 233,532 shares, decreasing direct ownership by 25% to 714,613 units (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- PRVir Biotechnology to Host Conference Call for First Quarter 2026 Financial ResultsVir Biotechnology, Inc. (NASDAQ:VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, May 6 to provide a corporate update and discuss its financial results for the first quarter ended March 31, 2026. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-mas
- SECSEC Form DEFA14A filed by Vir Biotechnology Inc.DEFA14A - Vir Biotechnology, Inc. (0001706431) (Filer)
- SECSEC Form DEF 14A filed by Vir Biotechnology Inc.DEF 14A - Vir Biotechnology, Inc. (0001706431) (Filer)
- PRVir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - Astellas to lead commercialization of VIR-5500 in the U.S. with Vir Biotechnology retaining option to co-promote, and Astellas obtaining exclusive rights to commercialize VIR-5500 ex-U.S. Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that its global collaboration and licensing agreement with Astellas announced on February 23, 2026 has closed following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The collaboration aims to accelerate the development of VIR-5500, a prostate-specific membrane antigen (PSMA)-targe
- PRVir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate CancerPhase 1 trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 in both early and late-line metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) Dose-expansion builds on promising Phase 1 monotherapy dose-escalation data in mCRPC presented in February 2026 Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the first patient has been dosed in one of three expansion cohorts in the Phase 1 trial evaluating VIR-5500, a prostate-specific membrane antigen (PSMA)-targeted, PRO-XTEN® dual-masked T-cell engager (TCE) for metastatic prostate cancer (NCT05997615). The Phase 1 trial is measuring
- SECSEC Form 8-K filed by Vir Biotechnology Inc.8-K - Vir Biotechnology, Inc. (0001706431) (Filer)
- INSIDERSEC Form 4 filed by De Backer Marianne4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- INSIDERSEC Form 4 filed by Sato Vicki L4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Vir Biotechnology Inc.SCHEDULE 13G/A - Vir Biotechnology, Inc. (0001706431) (Subject)
VIR FAQ
7 questionsWhat does Vir Biotechnology Inc. do?
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration...Where does VIR stock trade?
Vir Biotechnology Inc. (VIR) is listed on NASDAQ.What sector and industry is VIR in?
Vir Biotechnology Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Vir Biotechnology Inc. go public?
Vir Biotechnology Inc. (VIR) completed its IPO in 2019.What are analysts saying about VIR?
Vir Biotechnology Inc. has had 8 recent analyst actions on file. The most recent action was from Raymond James: Strong Buy with a $1900.00 price target on 2026-02-24. Recent price targets range from $900.00 to $3400.00.What companies are similar to VIR?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare VIR side-by-side with any of them on Quantisnow.How can I track VIR on Quantisnow?
Quantisnow aggregates Vir Biotechnology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VIR to receive live email and push alerts on every new disclosure.